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Abstract 19 
The putative protective role of the exopolysaccharide (EPS)-producing 20 
Lactobacillus paraplantarum BGCG11, and its non-EPS-producing isogenic strain 21 
NB1, was tested upon HT29-MTX monolayers challenged with seven opportunistic 22 
pathogens. The probiotic strain Lactobacillus rhamnosus LMG18243 (GG) was used as 23 
a reference bacterium. Tested lactobacilli were able to efficiently reduce the attachment 24 
to HT29-MTX of most pathogens. Lb. paraplantarum NB1 and Lb. rhamnosus GG 25 
were more efficient reducing the adhesion of Clostridium difficile or Yersinia 26 
enterocolitica than Lb. paraplantarum BGCG11, while strain BGCG11 reduced, to a 27 
greater extent, the adhesion of Escherichia coli and Listeria monocytogenes. The 28 
detachment and cell lysis of HT29-MTX monolayers in the presence of pathogens alone 29 
and co-incubated with lactobacilli or purified EPS was followed. L. monocytogenes 30 
induced the strongest cell detachment among the seven tested pathogens and this effect 31 
was prevented by addition of purified EPS-CG11. The results suggest that this EPS 32 
could be an effective macromolecule in protection of HT29-MTX cells from the 33 
pathogen-induced lysis. Regarding innate intestinal barrier, the presence of C. difficile 34 
induced the highest IL-8 production in HT29-MTX cells and this capability was 35 
reinforced by the co-incubation with Lb. paraplantarum NB1 and Lb. rhamnosus GG. 36 
However, the increase in IL-8 production was not noticed when C. difficile was co-37 
incubated with EPS-producing Lb. paraplantarum BGCG11 strain or its purified EPS-38 
CG11 polymer, thus indicating that the polymer could hinder the contact of bacteria 39 
with the intestinal epithelium. The measurement of mucus secreted by HT29-MTX and 40 
the expression of muc1, muc2, muc3B and muc5AC genes in the presence of pathogens 41 
and lactobacilli suggested that all lactobacilli strains are weak “co-adjuvants” helping 42 
some pathogens to slightly increase the secretion of mucus by HT29-MTX, while 43 
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purified EPS-CG11 did not induce mucus secretion. Taking altogether, Lb. 44 
paraplantarum BGCG11 could act towards the reinforcement of the innate mucosal 45 
barrier through the synthesis of a physical-protective EPS layer which could difficult 46 
the contact of the pathogens with the epithelial cells. 47 
 48 
Keywords: exopolysaccharide, Lactobacillus, pathogens, HT29-MTX, mucin, IL-8 49 
 50 
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1. Introduction 52 
Lactic acid bacteria (LAB) have been traditionally used in foods to preserve raw 53 
materials and to control fermentative processes for obtaining safe products with 54 
reproducible organoleptic characteristics. Selection of the appropriate starter or adjunct 55 
cultures to keep the “brand identity” of any fermented product is still of pivotal 56 
relevance. However consumers demand healthier products beyond their nutritional 57 
properties; thus, nowadays microbial cultures are also selected based on their functional 58 
traits (Leroy, & De Vuyst. 2004). In this context the development of functional foods 59 
containing beneficial microbes, known as probiotics, is a trending topic in the industrial 60 
food sector, as well as in the food science and technology research areas (Vasiljevic, & 61 
Shah, 2008). Probiotics are often defined as “live microorganisms, which when 62 
administered in adequate amounts confer a health benefit on the host” (WHO/FAO, 63 
2006; Hill et al., 2014). Probiotic bacteria most commonly used for human consumption 64 
belong to genera Lactobacillus and Bifidobacterium and milk products are the most 65 
common vehicles used for their delivery (Prasanna, Grandison, & Charalampopoulos, 66 
2014). It is worth noting that a rational selection of the best probiotic candidate(s) for a 67 
target human population(s) is highly recommended in order to obtain functional foods 68 
supporting health claims (Arboleya et al. 2012). Then these probiotics must be 69 
considered at strain level and only certain ones showing beneficial attributes should be 70 
consider for further applications. In this regard, strains having particular surface 71 
molecules that allow their interaction with the host are good candidates to be explored 72 
for probiotic formulations. 73 
 Exopolysaccharides (EPS) are carbohydrate polymers forming the external 74 
envelope of many bacteria which, apart from the ecological role for the producing 75 
bacteria, have technological, medical and industrial applications (Rehm, 2010). EPS-76 
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producing LAB are currently used in the manufacture of dairy fermentations due to their 77 
capability to improve the viscosity and texture of these products. Recently EPS from 78 
probiotics are receiving renewed interest due to their functional properties, being related 79 
in some cases with the health promoting activities of the producing bacteria. Several 80 
studies in vitro demonstrate the biological activities of EPS such as, among others: i) the 81 
capability to modulate the host immune response and the dynamic of the intestinal 82 
microbiota, ii) to antagonize against pathogens and iii) to act as physical barrier against 83 
toxic compounds, (Hidalgo-Cantabrana et al., 2014b). In addition, there are in vivo 84 
evidences using different animal models proving some of these beneficial properties. As 85 
an example in the context of this article, a single oral dose (9 Log CFU) of the EPS-86 
producing strain Lactobacillus johnsonii FI9785 administered to pathogen-free chicks 87 
was enough to eliminate Clostridium difficile infection (Dertli, et al. 2013; La Ragione, 88 
Narbad, Gasson, & Woodward, 2004).  89 
In a previous study, we have showed that the EPS-producing strain 90 
Lactobacillus paraplantarum BGCG11 isolated from a Serbian soft, white, home-made 91 
cheese, and three non-EPS-producing derivative strains, had probiotic traits. They 92 
survived (in enough number) to the adverse conditions of the gastrointestinal tract, they 93 
adhered at different degree to three intestinal epithelial cell (IEC) lines, and they were 94 
able to elicit different in vitro immune response upon peripheral blood mononuclear 95 
cells (Nikolic et al., 2012). Besides, the parental BGCG11strain was able to synthesise a 96 
ropy EPS-CG11 (Kojic, et al., 1992; Zivkovic et al. 2015), and given that derivative 97 
strains lost this character, the differences in probiotic attributes were partially ascribed 98 
to the presence / absence of the ropy polymer. The aim of the current work was to 99 
further characterise the EPS-producing Lb. paraplantarum BGCG11 strain and its non-100 
EPS-CG11 producing derivative NB1, in order to assess the putative protective role that 101 
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the polymer could play upon HT29-MTX monolayers challenged with some 102 
opportunistic pathogens that inhabit, or reach the gut through the diet. Several 103 
mechanisms of probiotic action against pathogen´s activity upon IEC were explored.  104 
. 105 
2. Material and Methods 106 
2.1. Bacterial strains and EPS purification 107 
The bacteria and culture conditions used in this study are listed in Table 1. As 108 
standard procedure, strain stocks stored at -80ºC were spread in agar-MRS (Biokar 109 
Diagnostics, Beauvais, France) or agar-BHI (Oxoid Limited, Hampshire, UK) and 110 
incubated for 48 h under optimal conditions for each strain. A single colony was picked 111 
up to inoculate 10 ml of the corresponding broth and incubated for 24 h. The cultures 112 
were used to inoculate (2%) fresh broth media which were incubated for 18 h to harvest 113 
cells for preparation of the bacterial suspensions needed in each experiment.    114 
 The EPS produced by Lb. paraplantarum BGCG11 (named EPS-CG11) was 115 
purified accordingly to the procedure previously reported by Nikolic et al. (2012), 116 
consisting in an initial extraction with ethanol precipitation, dialysis and freeze-dry, 117 
followed by a second purification with sequential DNAse type-I and Pronase E 118 
treatments, protein precipitation with TCA and ending with intensive dialysis and 119 
freeze-drying.     120 
2.2. HT29-MTX cell line culture conditions 121 
 The human colonocyte-like cellular line HT29-MTX (Lesuffleur, Barbat, 122 
Dussaulx, & Zweibaum, 1990) was used to test the capability of the two Lb. 123 
paraplantarum strains to counteract the effect of pathogens upon the intestinal 124 
epithelium. For this purpose, 1x10
5
 HT29-MTX cells were seed in 48-wells microplates 125 
(BD Falcon, BD Biosciences, NJ, USA) using complete-DMEM, i.e., DMEM medium 126 
supplemented with 10% foetal bovine serum and with a mixture of antibiotics (50 g/ml 127 
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penicillin, 50 g/ml streptomycin, 50 g/ml gentamicin and 1.25 g/ml amphotericin 128 
B). All reagents were purchased from Sigma (Sigma Chemical Co., St. Louis, MO, 129 
USA). Microplates were incubated at 37ºC, 5% CO2 in the CO2-Series Shel-Lab 130 
incubator (Sheldon Manufacturing Inc. OR, USA) until reach the differentiated and 131 
confluent (monolayer) state (12± 1 days post-seeding, about 1x10
7
 cells/ml). For co-132 
cultivation with bacterial strains, HT29-MTX monolayers were incubated under same 133 
conditions in the HERAcell 240 incubator (Thermo Electron LED GmbH, 134 
Langenselbold, Germany).   135 
2.3. Inhibition of pathogens adhesion to HT29-MTX by lactobacilli 136 
 The capability of the seven pathogens under study, together with the three 137 
lactobacilli used as reference, to adhere to the intestinal epithelium was tested. For that, 138 
bacterial cultures were washed twice with PBS and resuspended in DMEM without 139 
antibiotics at concentration 1x108 cfu/ml; this number was corroborated by plate 140 
counting in the agar-medium specific for each bacterium. The bacterial suspensions 141 
were independently added to the HT29-MTX monolayers at ratio (10: 1, bacteria: 142 
eukaryotic cell) and incubated at 37ºC, 5% CO2 for 1 h. Afterwards, monolayers were 143 
gently washed twice with Dulbecco´s PBS, to remove the non-attached bacteria, and the 144 
eukaryotic cells were released using 0.25% Trypsin-EDTA solution (Sigma). The 145 
samples were diluted in Ringer solution and plated to enumerate the bacteria adhered. 146 
The percentage of adhesion was calculated as follows: 100 x cfu bacteria adhered / cfu 147 
bacteria added. Each strain was tested in duplicated wells in two replicated HT29-MTX 148 
microplates (four data per strain). 149 
To test the capability of the two Lb. paraplantarum to inhibit the adhesion of 150 
pathogens to HT29-MTX monolayer, the seven pathogens were dyed with the SYTO9 151 
green-fluorescent nucleic acid stain (Molecular Probes, Life Technologies S.A., Madrid, 152 
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Spain). A working solution of 15 nM SYTO9 was prepared in complete-DMEM and 153 
added (volume / volume) to each bacterial suspension (final concentration 7.5 nM) 154 
prepared as previously described. Samples were incubated at room temperature, in 155 
darkness, for 2 h. To know the number of pathogens to be added to HT29-MTX, the 156 
fluorescence emitted at 512 nm (after excitation at 470 nm) of these pathogen samples 157 
was recorded in the Cary Eclipse fluorescence spectrophotometer (Varian Ibérica, S.A. 158 
Madrid, Spain). Afterwards, the fluorescence emitted was correlated with counts (log 159 
cfu) by means of linear regression equations calculated for each pathogen. The log cfu 160 
were obtained after plating in the corresponding agar-media (Table 1) serial dilutions in 161 
Ringer of an initial bacterial suspension of 1x10
8
 cfu/ml. The correlation coefficients 162 
(R
2
) of the equations obtained for the seven pathogens were 0.990±0.005. To know the 163 
inhibition capability of Lactobacillus strains, dyed pathogens were mixed with the 164 
lactobacilli suspensions (ratio 1:1). The dyed-pathogens alone were added to HT29-165 
MTX monolayers at ratio 10:1 (Fig. 1) as well as the combinations pathogen – 166 
lactobacilli, thus each bacterial type was added at ratio 5:1. Microplates were then 167 
incubated for 1 h at 37ºC, 5% CO2; afterwards, wells were gently washed twice with 168 
Dulbecco´s PBS and treated with 0.25% trypsine-EDTA solution. The fluorescence 169 
emitted by the pathogens adhered were measured in the fluorescence spectrophotometer 170 
and the corresponding log cfu were calculated using the linear regression equations. 171 
Finally, the percentage of adhesion was calculated as indicated above; within each 172 
pathogen, data were referred to that obtained with the pathogen alone (i.e. 100% 173 
adhesion) and finally, the pathogen adhesion reduction was calculated subtracting each 174 
referred value from 100. Each pair combination pathogen-lactobacilli, and the pathogen 175 
alone as reference, were tested in three replicated HT29-MTX microplates. 176 
2.4. Capability of lactobacilli to counteract the toxicity of pathogens upon HT29-MTX 177 
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Combinations of (non-dyed) pathogen–lactobacilli were prepared as indicated 178 
above (bacterial suspensions 1x108 cfu/ml in complete-DMEM, and ratio pathogen-179 
lactobacilii 1:1). In addition, each pathogen was resuspended in complete-DMEM 180 
supplemented with 1 mg/ml of EPS-CG11. The HT29-MTX monolayers were co-181 
cultivated with these bacterial combinations, as well as with the seven pathogens and 182 
the four probiotic factors added alone (Fig. 1), for 3 h at 37ºC, 5% CO2. The cell line 183 
was also incubated in the presence of complete-DMEM, which was used as reference 184 
control. Experiments were carried out in three replicated HT29-MTX microplates. At 185 
the end of the incubation, supernatants were collected and centrifugated (10,000xg, 4ºC, 186 
10 min) to remove the detached cells, before stored at -20ºC until use.  187 
2.4.1. Detachment of HT29-MTX monolayers 188 
 After supernatants collection, HT29-MTX cells were softly washed once with 189 
Dulbecco´s PBS, fixed with 2% formaldehyde (in PBS) for 1 min and washed again. 190 
Cells were stained with 0.13% crystal violet (in 5% ethanol and 2% formaldehyde-PBS) 191 
for 20 min at room temperature. Afterwards, wells were intensively washed with PBS 192 
solution, until obtain clear supernatants, and then the microplates were scanned (Ruas-193 
Madiedo et al. 2010).   194 
2.4.2. Lactate dehydrogenase activity 195 
 The levels of intracellular lactate dehydrogenase (LDH) released to the 196 
supernatants were quantified by means of the colorimetric Cytotoxicity Detection 197 
Kit
PLUS
 (Roche Diagnostics GmbH, Mannheim, Germany) following the manufacturer 198 
instructions. After enzymatic reaction, the absorbance of samples was measured at 450 199 
nm in the Modulus microplate photometer (Turner Biosystems, Sunnyvale, CA, USA). 200 
Data were referred to the reference control, i.e., to the values obtained in the HT29-201 
MTX wells incubated with complete-DMEM 202 
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2.5. Ability of lactobacilli to modify the innate intestinal barrier  203 
2.5.1. Production of IL-8 204 
 The supernatants were also used to quantify the production of the chemokine 205 
interleukin-8 (IL-8) by means of an ELISA test (eBioscience, Bender MedSystems 206 
GmbH, Vienna, Austria) following the manufacturer instructions. The colorimetric 207 
enzymatic reaction was measured at 450 nm in the Modulus microplate photometer and 208 
data were referred to the reference control. 209 
2.5.2. Production of mucin 210 
 Mucin production by Goblet cells present in HT29-MTX monolayers was 211 
quantified by using the fluorescence conjugated lectin Wheat Germ Agglutinin (WGA)-212 
Alexa Fluor 488 (Molecular Probes) as follows. HT29-MTX cells were grown in 96-213 
wells fluorometry validated microplates (Optilux™ Black/Clear Bottom, BD Falcon) 214 
under conditions described above until reach the monolayer state. Then bacterial 215 
suspensions were added following the experimental design described in Fig. 1; each 216 
condition was tested in duplicated wells in two replicated HT29-MTX microplates. 217 
Incubations were also carried out for 3 h at 37ºC, 5% CO2 and, finally, microplates were 218 
washed twice with Dulbecco´s PBS.  219 
For mucin detection, WGA-Alexa Fluor 488 was dissolved at 1 mg/ml in 220 
ultrapure water and a working solution of 5 g/ml was made in complete-DMEM. Then 221 
100 l of this solution was added to the washed HT29-MTX monolayer of each well 222 
and incubated at 37ºC, in darkness, for 1 h. After incubation, the non-attached WGA 223 
was eliminated washing twice with PBS, and finally 100 l of PBS was added. The 224 
fluorescence emitted at 518 nm by the monolayer, after sample excitation at 480 nm, 225 
was recorded in the Cary Eclipse fluorescence spectrophotometer and data were referred 226 
to the reference control. 227 
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2.5.3. Expression of MUC genes 228 
 Based on the results of mucin production, the pathogens C. difficile LMG21717 229 
and Escherichia coli LMG2092 were chosen to check the expression of some genes 230 
involved in the synthesis of mucin. For that purpose, HT29-MTX cells were seed in 12-231 
wells microplates (BD Falcon) and incubated until reach the monolayer state. Following 232 
the experimental design described in preceding sections (Fig. 1), the five combinations 233 
(pathogen-lactobacilli, pathogen-EPS or pathogen alone) were tested for each pathogen 234 
in three replicated microplates. HT29-MTX monolayers grown in complete-DMEM 235 
were also used as reference control. After a co-incubation for 3 h at 37ºC, 5% CO2, 236 
supernatants were removed and 0.5 ml of RNAlater solution (Ambion, Life 237 
Technologies S.A.) was added to each well to protect the RNA of the HT29-MTX cells. 238 
Then released cell samples were stored at -80ºC until use.  239 
Following the manufacturer´s instructions, the RNAaqueous-PCR kit 240 
(Ambion) was used for isolation of DNA-free RNA. The quantification of RNA was 241 
carried out in the Epoch apparatus (BioTek Instruments, Inc., Winoskii, VT, USA). For 242 
reverse-transcriptase PCR analyses 1 µg of RNA was reverse-transcribed to cDNA by 243 
using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Life 244 
Technologies S.A.). The generated cDNA was then stored at –80ºC until further 245 
analysis. 246 
Real-Time PCR was performed in an ABI Prism 7500 Fast Real-Time PCR 247 
System (Applied Biosystems). The TaqMan gene Master Mix and the TaqMan gene 248 
Expression Assays (Applied Biosystems) were used for MUC1 (Hs00159357_m1), 249 
MUC2 (Hs00159374_m1), MUC3B (Hs03649367_mH) and MUC5AC 250 
(Hs00873638_m1) analysis; the GAPD (glyceraldehyde-3-phosphate dehydrogenase) 251 
and ACTB (beta actin) were used for normalization of data. Expression levels were 252 
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determined by relative quantification using the Ct method (Livak & Schmittgen, 253 
2001) in which the expression level in the reference control (HT29-MTX cells grown 254 
alone) is arbitrarily set to 1 and the expression levels in the samples are calculated 255 
relative to that of the reference control. 256 
2.6. Statistical analysis 257 
Data were statistically analysed by using the SPSS/PC 19.0 software package 258 
(SPSS Inc., Chicago, IL, USA). After checking normal distribution of values, 259 
independent one-way ANOVA tests and, when needed, mean comparison LSD (least 260 
significant difference) tests, were used for analyses. The legend of figures or tables 261 
shows the statistical comparison performed for each type of parameter.   262 
 263 
3. Results 264 
3.1. Bacterial antagonism for adhesion to HT29-MTX 265 
 The capability of the enteropathogens and lactobacilli strains used in this study 266 
to adhere to the epithelial cell line HT29-MTX was highly variable (Fig. 2A). Most 267 
pathogens showed low adhesion percentage (< 5%) and all of them, except C. difficile 268 
and E. coli, adhered significantly less than the strain Lb. rhamnosus LMG18243 (= GG) 269 
used as reference. The two Lb. paraplantarum strains manifested a considerable 270 
difference in their adhesiveness to the colonocytes as we have previously reported 271 
(Nikolic et al., 2012). The strain BGCG11, producing the ropy EPS-CG11, showed an 272 
adhesion percentage similar to that of GG; the derivative NB1 strain, which has lost the 273 
30 kb plasmid carrying the genes (operon) for the synthesis of the ropy EPS, almost 274 
doubled its adhesion ability comparing to the parental strain.  275 
 The antagonism of the three lactobacilli against pathogen´s adhesion to HT29-276 
MTX monolayers varied according to the pathogenic strain (Fig. 2B).  The highest 277 
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reduction of adhesion (around 45%) was detected when Shigella sonnei was co-278 
incubated in the presence of the lactobacilli, although no significant differences were 279 
detected among the three strains. On the contrary, the lowest reduction (< 8%) was 280 
showed when C. difficile competed with the lactobacilli for adhesion to HT29-MTX. 281 
However, in this case, significant differences among lactobacilli strain used were 282 
denoted. Indeed, probiotics were able to efficiently reduce the attachment of most 283 
pathogens and the performance of the three strains was, in general, similar although 284 
their efficacy was dependent on the pathogen considered. For example, Lb. 285 
paraplantarum NB1 and Lb. rhamnosus GG were more efficient reducing the adhesion 286 
of C. difficile or Yersinia enterocolitica than Lb. paraplantarum BGCG11. However, 287 
the latter strain reduced in higher extent the adhesion of E. coli and Listeria 288 
monocytogenes.   289 
3.2. Response of the cell line HT29-MTX 290 
 To test the protection that the lactobacilli or the EPS-CG11 could confer to 291 
HT29-MTX cells challenged with the seven pathogens, the monolayers were stained 292 
with crystal violet after co-cultivation of bacterial factors with eukaryotic cells (Fig. 293 
3A). L. monocytogenes LMG13305 presented the stronger cell detachment of the seven 294 
pathogens added alone since only few cells remained adhered to the bottom of the 295 
microplate; other pathogens showed variable degrees of detachment. Remarkably, the 296 
purified EPS-CG11, added to the wells at the same time than the pathogens, was the 297 
most effective treatment to keep adhered the HT29-MTX cells, even better than the 298 
EPS-producing BGCG11 strain or the other two lactobacilli. Aiming to check whether 299 
the monolayer disaggregation was due to cellular lysis, the levels of the cytoplasmic 300 
LDH were determined in the supernatants of these co-cultures (Fig. 3B). Again, L. 301 
monocytogenes was the pathogen causing the highest LDH release and, although the 302 
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differences were not statistically significant, it seems that the presence of the purified 303 
EPS-CG11 protected HT29-MTX for the listeria-induced lysis. Similar tendency was 304 
detected with the other pathogens as well. However, it is worth noting that lactobacilli, 305 
either intact bacteria or purified EPS, were only able to significantly reduce the cellular 306 
damage induced by C. dificille. 307 
When intestinal epithelium encounters pathogens, the enterocytes, acting at first 308 
barrier of the innate immune response, are able to release signalling molecules such as 309 
interleukin (IL)-8. Levels of IL-8 released by HT29-MTX, relative to the basal values 310 
(control sample), varied depending on the pathogen tested (Fig. 4). C. difficile alone 311 
induced the highest IL-8 production and this capability was reinforced by the presence 312 
of Lb. paraplantarum NB1 and Lb. rhamnosus GG, but no by the EPS-producing Lb. 313 
paraplantarum BGCG11 strain or its purified polymer. Indeed, the three probiotic 314 
lactobacilli themselves were able to induce IL-8 secretion in higher levels than some 315 
pathogens (relative IL-8 production: 3.890.92, 6.282.4 and 3.741.54 for BGCG11, 316 
N1, and GG strains, respectively), but the purified EPS-CG11 (0.50.22) was not. As 317 
stated in previous sections, it is not possible to stand out one of the three lactobacilli 318 
given that the strain BGCG11 seemed to be as good, or even better, than the other two 319 
at inducing the release of IL-8 induced by other pathogens (e.g. L. monocytogenes, E. 320 
coli, Sh. sonnei and Y. enterocolitica).  321 
Another mechanism to keep the innate barrier at intestinal epithelium level is the 322 
secretion of glycoproteins, known as mucins, which form a protective layer (mucus) in 323 
the luminal side of the gut. The fluorescent lectin WGA was used to quantify the 324 
production of mucins by HT29-MTX in the experimental conditions of this study (Fig. 325 
5). In general, the relative production of mucins, with respect to the basal level, was not 326 
high. The production was increased in the presence of C. difficile and, specially, when it 327 
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was simultaneously co-incubated with Lb. rhamnosus GG (p<0.05). This pathogen, as 328 
well as E. coli selected as no mucin-inducing control, was used to achieve the 329 
expression analysis of some muc genes (Table 2). These results confirmed that the 330 
relative expression level of muc1, muc2, muc3B and muc5AC was not high, which 331 
correlate with the few level of mucin amount detected. As expected E. coli did not 332 
induced the expression of any muc gen, whereas C. difficile, in combination with Lb. 333 
rhamnosus GG and Lb. paraplantarum BGCG11, promoted higher expression of 334 
muc3B by HT29-MTX than when the pathogen was added alone.  335 
 336 
4. Discussion 337 
 Among the health promoting properties of probiotic strains, the capability to 338 
counteract the negative effects of pathogens is one of the desired traits (WHO/FAO, 339 
2006). Indeed, it has been probed that probiotic formulations, containing mainly 340 
lactobacilli, are effective to treat or prevent infectious diarrhoea caused by the use of 341 
antibiotics or by recurrent C. difficile infections in humans (Sanders et al., 2014; Tojo et 342 
al., 2014). The probiotic antagonism against pathogens is a strain-dependent 343 
characteristic and several mechanisms of action have been proposed; probiotics might i) 344 
provide a physical barrier blocking the pathogen entry (colonization competition), ii) 345 
induce the mucus production, iii) reinforce the selective permeability of the epithelium 346 
by increasing tight-junctions, iv) produce antimicrobial factors, and/or v) stimulate the 347 
innate immune response, among others (Gareau, Sherman, & Walker, 2010; Liévin-Le 348 
Moal, & Servin, 2014). Some of these mechanisms involve the direct interaction of 349 
probiotics with the host cells which, in turns, modifies their response against the 350 
pathogens.. In this study we have explored potential mechanisms of action that could 351 
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explain the antagonism among two Lb. paraplantarum strains, differing in their 352 
capability to produce a ropy EPS, and several intestinal pathogens.  353 
4.1. Lactobacilli strains reduced pathogen adhesion to HT29-MTX  354 
Regarding competition for the colonization of intestinal niche, the three 355 
lactobacilli reduced in different degree the adhesion of the seven pathogens to HT29-356 
MTX monolayers having similar performance, i.e. none of the strains showed greater 357 
inhibition. There are several reports in literature showing the capability of different 358 
lactobacilli species to reduce the adhesion of diverse enteropathogens to intestinal cells, 359 
either cellular lines (Caco2, HT29 or HT29-MTX) or IEC isolated from animals 360 
(García-Cayuela et al., 2014). This capability has been attributed to the production of 361 
antibacterial factors, such as bacteriocins or organic acids (Kaewnopparat et al., 2013; 362 
Satish-Kumar et al., 2011), as well as to the presence of specific structural components 363 
in the surface of the lactobacilli. It has been indicated that these components are cell 364 
surface associated proteins (Varma, Dinesh, Menon, & Biswas, 2010) or S-layer 365 
macromolecules built from proteins (Zhang et al., 2010). The putative mechanisms 366 
behind the reduction of pathogen attachment to IEC are a steric hindrance of lactobacilli 367 
avoiding the interaction of the pathogen (Satish-Kumar et al. 2011) and also co-368 
aggregation phenomena (Kaewnopparat et al., 2013). However, co-aggregation could 369 
also increase the number of pathogens “apparently” adhered to the IEC if the 370 
lactobacilli co-aggregated with the pathogen shows good adhesion properties (Ayeni et 371 
al., 2011; Gueimonde, Jalonen, He, Hiramatsu, & Salminen, 2006). This is not 372 
necessarily a negative trait since the formation of co-aggregates will facilitate the closer 373 
antibacterial activity of lactobacilli and, if the pathogen is linked to the bacteria surface, 374 
it will not be able to adhere to the IEC. This statement has been previously underlined in 375 
studies carried out with EPS-producing lactobacilli and bifidobacteria interfering with 376 
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the adhesion of pathogens to human intestinal mucus (Ruas-Madiedo, Gueimonde, 377 
Margolles, de los Reyes-Gavilán, & Salminen, 2006a). Indeed, it was demonstrated the 378 
role that EPS plays in this interference working with the polymer purified from the 379 
Scandinavian fermented milk “viili”, which is synthesized by Lactococcus lactis subsp. 380 
cremoris (Ruas-Madiedo, Gueimonde, de los Reyes-Gavilán, & Salminen, 2006b). In 381 
the current study we cannot discard that the ropy EPS-CG11 plays a role in the 382 
pathogen adhesion inhibition of some of the pathogens analysed; but its absence in the 383 
derivative strain NB1 was not an impediment to favor equal or even higher inhibition in 384 
some pathogenic strains.  385 
4.2. Lactobacilli strains reduced HT29-MTX damage induced by some pathogens 386 
 Lactobacillus species and probiotics in general, could protect host against 387 
pathogens invasion improving the barrier of the intestinal mucosa by reinforcing the 388 
integrity of the intestinal epithelium (Nissen, Chingwaru, Sgorbati, Biavati, & Cencic, 389 
2009).  Some surface components (S-layer) from lactobacilli are able to maintain the 390 
intestinal epithelium integrity avoiding the cellular damage produced by some 391 
pathogen´s toxins (Carasi, Trejo, Pérez, De Antoni, & Serradell, 2012). In the case of 392 
the Lb. paraplantarum BGCG11 under study, it seems that its purified EPS could be an 393 
effective macromolecule protecting HT29-MTX cells from the lysis induced by some 394 
pathogens. The EPS could form a layer, a kind of “protective biofilm”, covering the 395 
intestinal cells thus avoiding either the interaction of the toxins with their eukaryotic 396 
receptors or acting as toxin-scavenger agents (Ruas-Madiedo et al., 2010). Indeed, it 397 
was demonstrated that the EPS kefiran, purified from the fermented milk kefir, is able 398 
to abrogate the cytotoxic effect of extracellular factors released by Bacillus cereus upon 399 
Caco-2 cells, the effect being EPS-dose dependent (Medrano, Pérez, & Abraham, 2008).  400 
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 Along the gastrointestinal tract, the intestinal mucosa is covered by a highly 401 
viscous, complex and thick layer of mucus composed of mucin glycoproteins and other 402 
molecules related with host defense against pathogens (McGuckin, Lindén, Sutton, & 403 
Florin, 2011). It has been demonstrated in animal model that some lactobacilli, such as 404 
Lactobacillus fermentum, are able to in vivo increase the number of Goblet mucin-405 
secretory cells as well as the expression of muc genes (Cao, Yang, Sun, Chanjuan, & 406 
Yao, 2012). Nevertheless, most studies with probiotics explore their capability to in 407 
vitro adhere to this mucus layer and, in a few of them, it was reported that the ability of 408 
probiotics to inhibit pathogens adhesion is due to the up-regulation of mucus secretions 409 
(Mack, Michail, Wei, McDougall, & Hollingsworth, 1999). In some cases is enough the 410 
presence of bacterial-cell extracts to stimulate the mucin production; those obtained 411 
from Lb. acidophilus induce muc2 expression, contributing to the inhibition of E. coli 412 
O157:H7 attachment to HT29 intestinal epithelial cells (Kim, Kim, Whang, Kim, & Oh, 413 
2008). Results obtained in our study suggest that the actobacilli,  could act as weak “co-414 
adjuvants” helping some pathogens, such as C. difficile, to slightly increasing the 415 
secretion of mucus by HT29-MTX. The poor differences detected in the expression of 416 
muc3B gene between the two Lb. paraplantarum strains does not allow obtaining any 417 
conclusion about the contribution of the ropy EPS-CG11 in mucus secretion. In any 418 
case, the purified polymer itself was not able to improve the expression of muc genes, 419 
nor the secretion of mucus. Thus, it seems that the EPS from Lb. paraplantarum is not 420 
an extracellular factor inducing mucus secretion. 421 
A recent review indicates that several probiotic lactobacilli diminish the 422 
production of pathogen-induced IL-8 by intestinal epithelial cells (Liévin-Le Moal, & 423 
Servin, 2014). However, the results obtained with both Lb. paraplantarum strains, as 424 
well as with Lb. rhamnosus GG, pointed to the opposite direction; the production of IL-425 
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8 promoted by enteropathogens was stimulated in the presence of the three lactobacilli, 426 
whereas the purified ropy EPS-CG11 had not effect itself, probably, because would 427 
difficult the contact between the bacteria and the intestinal epithelium. In this regard, we 428 
can found in literature data supporting our results, that is a lactobacilli-mediated 429 
induction of IL-8 secretion (Kim et al., 2008; Seifert et al., 2010; Vizoso-Pinto et al., 430 
2007); but also the contrary, a down regulation of IL-8 production promoted by 431 
lactobacilli (Candela et al., 2008; Dhanani, & Bagchi, 2013; Nandakumar, Pugazhendhi, 432 
Madhu-Mohan, Jayakanthan, & Ramakrishna, 2009; O'Hara et al., 2006). These 433 
apparently contradictory results indicates that the capability to modulate the levels of 434 
this chemokine is highly dependent on the Lactobacillus strain considered and, 435 
probably, dependent as well on the IL-8 inductor pathogen. Besides, the influence of the 436 
intestinal epithelial cellular model used cannot be obviated (Hidalgo-Cantabrana et al., 437 
2014a). The ability of Lactobacillus species to moderately increase the production of 438 
IL-8 in the presence of pathogens could be a beneficial trait since this chemokine will 439 
contribute to the recruitment of neutrophils to combat infection; therefore, this will be 440 
another probiotic mechanism to reinforce the intestinal innate defense.  441 
 442 
5. Conclusion 443 
 The strains Lb. paraplantarum BGCG11 and NB1, as well as Lb. rhamnosus 444 
GG, seemed to induce the synthesis of cellular factors (IL-8 and mucins) by HT29-445 
MTX monolayers challenged with pathogens which, in a physiological situation, could 446 
help to improve the intestinal barrier. The performance of the three lactobacilli was 447 
similar since we could not found any strain that behave better than the others. In 448 
addition, the ropy EPS-CG11 synthesised by the strain Lb. paraplantarum BGCG11 449 
was able to partially counteract the cellular damage (release of LDH) caused by some 450 
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pathogens. Therefore, both Lb. paraplantarum strains are promising probiotic 451 
candidates effective against intestinal pathogens, especially C. difficile.   452 
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Table 1 Bacterial strains and culture conditions used in this study 623 
 624 
Strain Origin Culture conditions 
3
 
Lactobacillus paraplantarum BGCG11 Artisanal cheese (natural isolate)
 1
 MRS, 30ºC, aerobic 
Lactobacillus paraplantarum NB1 Novobiocin-cured from BGCG11-
derivative (lacking the 30 kb 
plasmid carrying the EPS operon) 
1
 
MRS, 30ºC, aerobic 
Lactobacillus rhamnosus LMG18243 (GG) BCCM 
2
 MRS, 37ºC, anaerobic 
Clostridium difficile LMG21717 BCCM BHI, 37ºC, anaerobic 
Salmonella enterica serotype Typhimurium 
LMG15860 
BCCM BHI, 37ºC, anaerobic 
Listeria monocytogenes LMG13305 BCCM MRS, 37ºC, aerobic 
Cronobacter sakazakii LMG5740 BCCM BHI, 37ºC, anaerobic 
Escherichia coli LMG2092 BCCM BHI, 37ºC aeration  
Shigella sonnei LMG10473 BCCM BHI, 37ºC, anaerobic 
Yersinia enterocolitica LMG7899 BCCM BHI, 37ºC, anaerobic 
1
 Described in Kojic et al., 1992; Nikolic et al., 2012. 625 
2
 Belgian Coordinated Collections of Microorganisms. 626 
3 
The anaerobic conditions were achieved in the chamber MG500 (Don Whitley Scientific, Yorkshire, UK) under 80% N2, 10% H2, 10% CO2 atmosphere. The 627 
aeration was achieved in the Excella E24 Incubator Shaker (New Brunswick Scientific, Enfield, CT, USA). 628 
 629 
  630 
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Table 2 Expression of MUC genes in HT29-MTX in the presence of pair combinations 631 
pathogen and lactobacilli or EPS-CG11..  632 
  Relative expression (mean ± SD) 2 
Gene1 Probiotic factor C. difficile LMG21717 E. coli LMG2092 
muc1 Pathogen (alone) 
+ L. paraplantarum BCG11 
+ L. paraplantarum NB1 
+ L. rhamnosus LMG18243 
+ EPS-CG11 
1.34±0.11 
1.37±0.07 
0.98±0.35 
1.24±0.20 
1.24±0.06 
1.17±0.29 
1.28±0.11 
1.12±0.04 
1.09±0.30 
1.08±0.22 
muc2 Pathogen (alone) 
+ L. paraplantarum BCG11 
+ L. paraplantarum NB1 
+ L. rhamnosus LMG18243 
+ EPS-CG11 
0.92±0.09 
1.10±0.02 
1.17±0.48 
1.34±0.79 
0.57±0.03 
0.91±0.69 
0.94±0.28 
0.85±0.29 
0.85±0.58 
0.62±0.03 
muc3B Pathogen (alone) 
+ L. paraplantarum BCG11 
+ L. paraplantarum NB1 
+ L. rhamnosus LMG18243 
+ EPS-CG11 
1.11±0.46
 ab
 
1.78±0.29
 c
 
0.80±0.46
 a
 
1.47±0.15
 bc
 
0.95±0.12
 ab
 
* 
1.47±0.37 
1.36±0.58 
1.49±0.71 
1.13±0.38 
2.07±1.22 
muc5AC Pathogen (alone) 
+ L. paraplantarum BCG11 
+ L. paraplantarum NB1 
+ L. rhamnosus LMG18243 
+ EPS-CG11 
1.35±0.12 
1.38±0.28 
1.11±0.75 
1.29±0.51 
1.44±0.50 
0.79±0.46 
0.87±0.18 
0.76±0.14 
0.77±0.38 
1.18±0.31 
1 The expression of MUC genes was normalize by the housekeeping gapdh 633 
(glyceraldehyde-3-phosphate dehydrogenase) and actb (actin, beta) genes and 634 
calculated relative to that of the reference control (cell line grown in DMEM alone). 635 
2 Within each pathogen, data were analysed by means of one-way ANOVA test and the 636 
statistical differences were annotated with asterisks (*p<0.05). The mean comparison 637 
LSD was used to asses differences among probiotic factors; in this case, means that do 638 
not share a common superscript letter are significantly different (p<0.05). 639 
  640 
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Figure legends 641 
Fig. 1 Experimental design used to test the capability of two Lb. paraplantarum and the 642 
reference Lb. rhamnosus LMG18243 (GG) strains, as well as that of the EPS-CG11, to 643 
counteract the effect of seven pathogens upon the intestinal cell line HT29-MTX. 644 
Combinations of pathogen and lactobacilli were mixed at ratio 1:1 (final bacteria 1x10
8
 645 
cfu/ml) and added to HT29-MTX confluent monolayers at ratio 10:1 (bacteria : 646 
eukaryotic cell). Pathogens were resuspended in DMEM supplemented at 1 mg/ml with 647 
EPS-CG11. Probiotic factors and pathogens were also tested alone and several wells 648 
were kept as reference control (cultivated in DMEM without any factor added).  649 
 650 
Fig. 2 (A) Percentage of adhesion of the nine strains used in this study. Each strain was 651 
compared with the reference Lb. rhamnosus LMG18243 (GG) strain by means of an 652 
one way ANOVA test and asterisks denoted significant differences (* p<0.05, ** 653 
p<0.01).  (B) Percentages of pathogen-adhesion reduction were calculated in the 654 
presence of the three lactobacilli. Within each pathogen, those bars that do not share a 655 
common letter are significantly (p<0.05) different accordingly to the mean comparison 656 
LSD test.  657 
 658 
Fig. 3 (A) Crystal violet staining of HT29-MTX monolayers after co-cultivation with 659 
different bacterial factors. (B) Relative (to the control culture) LDH (lactate 660 
dehydrogenase) released to the supernatants of HT29-MTX monolayers co-cultured 661 
with different bacterial factors. Within each pathogen, those bars that do not share a 662 
common letter are significantly (p<0.05) different accordingly to the mean comparison 663 
LSD test.  664 
 665 
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Fig. 4 Relative (to the control culture) IL-8 (interleukin) production by HT29-MTX 666 
monolayers co-cultivated with different bacterial factors. Within each pathogen, those 667 
bars that do not share a common letter are significantly (p<0.05) different accordingly 668 
to the mean comparison LSD test. 669 
 670 
Fig. 5 Relative (to the control culture) mucin production by HT29-MTX monolayers co-671 
cultivated with different bacterial factors. Within each pathogen, those bars that do not 672 
share a common letter are significantly (p<0.05) different accordingly to the mean 673 
comparison LSD test. 674 
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